Jounce Therapeutics reports new clinical data on vopratelimab

Jounce Therapeutics reported new clinical data on vopratelimab at the American Association for Cancer Research Annual Meeting. “The Jounce poster presentations show that patients in the ICONIC trial with emergence of ICOS hi CD4 T cells have improved progression free survival and overall survival compared to patients with ICOS lo CD4 T cells. Data related to important immune characteristics of ICOS hi CD4 T cells were also presented,” said the company. Three groups of Iconic relapsed refractory solid tumor patients were compared in the new analysis: 18 patients who have demonstrated ICOS hi CD4 T cells in the blood, 32 patients who have demonstrated ICOS lo CD4 T cells, and a group of patients enrolled in parts A through D which includes an additional 151 patients that were not tested for ICOS status due to lack of samples, according to Jounce. It added, “The emergence and persistence of the ICOS hi CD4 T cell biomarker in the peripheral blood is associated with improved PFS and OS: All benefit in the study, measured by tumor reductions, PFS and OS, was in the ICOS hi CD4 T cell group; PFS: median 6.2 months for patients with ICOS hi CD4 T cells vs 2 months for both patients with only ICOS lo CD4 T cells and All Patients; OS: median not yet reached for patients with ICOS hi CD4 T cells vs 9 months for patients with only ICOS lo CD4 T cells and 9.1 months for All Patients.” Richard Murray, CEO of Jounce Therapeutics, said, “We are encouraged by the improved PFS and OS data associated with the emergence of the ICOS hi CD4 T cell biomarker and are convinced that meaningful advancements in immuno-oncology will require the type of science-based translational understandings that the Jounce team and platform have enabled to advance vopratelimab thus far. We have established our translational technology base for the purpose of creating a preclinical and, more importantly, clinical scientific understanding of the mechanism of action of new immunotherapies and the characteristics of responding versus non-responding patients to focus the next steps of clinical development for vopratelimab and our pipeline.”
https://thefly.com/landingPageNews.php?id=2887593